Procter & Gamble (PG) Offering Possible 7.99% Return Over the Next 8 Calendar Days

Procter & Gamble's most recent trend suggests a bullish bias. One trading opportunity on Procter & Gamble is a Bull Put Spread using a strike $132.00 short put and a strike $127.00 long put offers a potential 7.99% return on risk over the next 8 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $132.00 by expiration. The full premium credit of $0.37 would be kept by the premium seller. The risk of $4.63 would be incurred if the stock dropped below the $127.00 long put strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Procter & Gamble is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Procter & Gamble is bullish.

The RSI indicator is at 79.57 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Procter & Gamble

Clorox vs Procter & Gamble: Which Consumer Staples Stock is More Attractive?
Wed, 12 Aug 2020 06:12:41 +0000
Typically, investors consider consumer staple stocks as safe bets during economic slowdowns or recessions. The defensive nature of consumer staples and attractive dividends make them desirable during challenging times.Generally, consumer staples do not deliver spectacular sales growth rates. However, COVID-19 changed that for some companies like Clorox. Heightened focus on sanitizing and cleaning led to a major spike in Clorox’s sales. Procter & Gamble is another staples company that benefited from higher pandemic-led demand for some of its products.Using the TipRanks’ Stock Comparison tool, we lined up the two staples alongside each other to see which stock offers the most compelling investment opportunity right now.Clorox (CLX)Clorox has been experiencing an unprecedented demand for its disinfecting and cleaning products since the COVID-19 outbreak. The company finished fiscal 2020 on a strong note with consumers stocking up its namesake Clorox bleach brand and other cleaning products to fight the pandemic. Despite additional capacity, many of the company’s products went out of stock due to the elevated demand.In the fiscal fourth quarter (April to June quarter), Clorox’s sales surged 22% year-over-year to $1.98 billion. The top line was supported by double-digit growth across all the four segments – Health and Wellness, Household, Lifestyle and International. The Health and Wellness segment’s sales were up 33%, driven by strong sales of cleaning products.The stay-at-home mandates helped in driving higher sales of bags and wraps as well as grilling products and led to a 17% increase in the Household segment’s sales. The Health and Wellness and Household segments together accounted for over 71% of Clorox’s fourth-quarter sales. Impressive fourth-quarter sales led to an EPS of $2.41, reflecting a 28.2% year-over-year growth. However, higher manufacturing and logistics costs as well as advertising investments were a drag on the bottom line.Increased cleaning and hygiene needs might continue to benefit Clorox. However, the rate of sales growth might not be as strong as that in the fiscal fourth quarter. The company’s fiscal 2020 sales and EPS grew by 8.2% and 16.5%, respectively. Clorox predicts a flat to low single-digit rise in its fiscal 2021 sales and a mid-single-digit decline to mid-single-digit growth in EPS.Clorox aims to boost its sales through innovation. Also, recent strategic partnerships with United Airlines, Uber Technologies, AMC Theaters and Cleveland Clinic to maintain safety protocols amid the pandemic are expected to further enhance sales.Clorox stock has gained 52% year-to-date. Despite robust sales momentum, several analysts are on the sidelines due to valuation concerns. Following the fiscal fourth-quarter results, Credit Suisse analyst Kaumil Gajrawala raised the price target for Clorox stock to $200 from $185 while maintaining a Neutral rating.He noted, “Clorox delivered a strong quarter behind continued elevated demand across its portfolio due to COVID-19. Capacity shortage, particularly in cleaning and disinfecting products, has been met with inventory drawdowns and new co-packers. Firm is investing aggressively behind its brands and increased production. This should support high rates of growth through the remainder of 2020 as consumption shows little signs of abating and inventories (both company and channel) still need to get replenished. Valuation keeps us on the sidelines.”Overall, Clorox has a Hold analyst consensus rating from the Street based on 2 Buys, 5 Holds and 2 Sells. The average price target of $223.33 implies a possible decline of 4.3% over the next year. (See Clorox stock analysis on TipRanks)Procter & Gamble (PG)Leading staples firm Procter & Gamble is recognized worldwide through several popular brands, including Ariel, Gillette, Head & Shoulders, Pampers and Tide. Since the COVID-19 crisis, Procter & Gamble has been experiencing higher demand for categories like fabric care, home cleaning and dishwashing products, as well as baby, feminine and family care products. The company’s personal health care business also gained from pandemic-led demand.However, movement restrictions and travel disruptions to curb the virus have hurt the sales of some of the company’s beauty and grooming products. Overall, Procter & Gamble’s fiscal fourth-quarter sales of $17.7 billion were up 3.5% year-over-year. The fourth-quarter adjusted EPS grew by 5.5% to $1.16. Higher sales coupled with productivity savings drove the earnings growth.Summarizing fiscal 2020, the company’s sales and EPS rose 4.8% and 13.3%, respectively. Looking ahead, Procter & Gamble expects sales growth of 1% to 3% in fiscal 2021. It predicts fiscal 2021 adjusted EPS growth in the range of 3% to 7%. The company’s conservative guidance compared to fiscal 2020 reflects the impact of a challenging macro environment, the corona crisis and intense competition.Procter & Gamble stock has risen 7% year-to-date and several analysts raised their price target for PG following the company’s fiscal fourth-quarter results. Berenberg Bank analyst James Targett upped his price target to $136 from $123.In a research note, he explained, “We understand investors’ current attraction to P&G due to its categories, balance sheet, buyback and dividend. These factors position it well into FY21. P&G is showing encouraging market share momentum (up 50bp globally in Q4), with higher shares online, and management again reiterated that P&G’s product offer is better positioned than in the previous recession.” However, the analyst maintained his Hold rating owing to “less exciting” valuation.Procter & Gamble has a cautiously optimistic Moderate Buy analyst consensus rating based on 8 Buys and 4 Holds. The Street’s average price target of $141.08 reflects an upside potential of 5.21% over the next 12-months. (See Procter & Gamble stock analysis on TipRanks)So which stock is better?Both Clorox and Procter & Gamble might continue to enjoy strong demand for certain categories, especially cleaning products, even when the pandemic fades. However, Wall Street consensus rating, upside potential and Clorox’s comparatively lofty valuation make Procter & Gamble a more compelling investment. Procter & Gamble’s current dividend yield of 2.36% compared to Clorox’s 1.90% also acts in its favor.To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment More recent articles from Smarter Analyst: * Zoom Video Drops 8% After Salesforce Sells Off Stake * J2 Global Surges 15% On Earnings Beat; RBC Upgrades To ‘Buy’ * Boeing’s Aircraft Deliveries Drop In July As More 737 MAX Cancellations Hit * MPLX Prices $3B Public Offering; RBC Capital Bullish On Outlook

Diamond Hill Capital's Top 5 Buys in the 2nd Quarter
Tue, 11 Aug 2020 23:01:31 +0000
Ohio-based firm's top buys include United Technologies spinoff Continue reading…

Why Procter & Gamble Is Cautious About 2021
Tue, 11 Aug 2020 15:45:00 +0000
Investors liked what they heard from Procter & Gamble (NYSE: PG) last week as the company closed out its best fiscal year in over a decade. Sales gains beat management's target for the fourth consecutive quarter, and cash flow and profitability each ticked higher. CEO David Taylor and his team broke down the factors behind their updated outlook in a conference call with investors, and below are a few highlights from that presentation.

3 Top Stocks to Recession-Proof Your Portfolio
Tue, 11 Aug 2020 11:15:00 +0000
This recession is unusual since it was caused by a public health crisis instead of macroeconomic problems, and it's unclear if the economy will rebound after the pandemic ends. Let's focus on three names that should hold up well during an economic slowdown: Procter & Gamble (NYSE: PG), Dollar General (NYSE: DG), and Veeva Systems (NYSE: VEEV). P&G owns a broad portfolio of billion-dollar consumer brands like Bounty, Charmin, Crest, Head & Shoulders, Gillette, Pampers, Pringles, and Tide.

Oral-B® Guide with Amazon Alexa Built-in Powers Truly Connected Bathroom
Mon, 10 Aug 2020 12:03:00 +0000
Procter & Gamble announced today that the Oral-B Guide, a smart brushing solution featuring the first voice-integrated toothbrush, is now available.

Be Sociable, Share!

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.